Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anemia 3Uterine Cervical Neoplasms 2Rectal Neoplasms 1Radiation Injuries 1Neoplasms 1Lichen Planus, Oral 1Gastrointestinal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 51Capecitabine 42Irinotecan 29Bevacizumab 21Radiotherapy 17Cetuximab 12Folfox protocol 11Chemoradiotherapy 11Neoadjuvant Therapy 10Chemotherapy, Adjuvant 9Surgical Procedures, Operative 6Drug Therapy 6XELOX 5Panitumumab 4Laparoscopy 4FOLFOXIRI protocol 4Transanal Endoscopic Microsurgery 3Radiation 3Octreotide 3IFL protocol 3Floxuridine 3Diathermy 3Celecoxib 3vatalanib 2spartalizumab 2Trinitrotoluene 2Tegafur 2Semaxinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Rectal Neoplasms × Erythropoietin × Clear all
NCT00254436 2018-10-25

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡